Syndax Highlights 12 Revuforj Abstracts Accepted for EHA 2026
Syndax Pharmaceuticals had 12 Revuforj (revumenib) abstracts accepted for presentation at the European Hematology Association 2026 Congress, covering real-world, frontline, post-transplant maintenance, and relapsed/refractory AML data across KMT2Ar, NPM1m, and NUP98r subtypes. Abstracts include updated Phase 1 and combination trial results and maintenance outcomes.
1. Abstract Acceptance
Syndax had 12 Revuforj abstracts accepted for presentation at the European Hematology Association 2026 Congress, scheduled June 11–14 in Stockholm. Accepted formats include both poster and oral sessions, with presentations spanning multiple time slots.
2. Key Data Highlights
The abstracts encompass real-world findings from the ROAR study in relapsed/refractory acute leukemia, updated Phase 1 frontline results combining revumenib with intensive chemotherapy in NPM1m, KMT2Ar and NUP98r AML, maintenance outcomes following hematopoietic stem cell transplantation, and combination data from SAVE and AUGMENT-101 programs.
3. Clinical Implications and Next Steps
The breadth of data reinforces Syndax’s leadership in menin inhibition and underscores revumenib’s potential to reduce relapse risk, drive high MRD negativity and transplant rates. Full poster presentations will be made available on the company website once the embargo lifts, supporting upcoming pivotal trials.